Better Choice expects combined 2025 revenue ~$270M, EBITDA ~$10M; SRx Health acquisition close imminent

SRx Health Solutions, Inc.

Combined 2025 pro forma revenue over $270M and EBITDA over $10M, based on management assumptions.
Transaction expected to close late Q4 2024 or early Q1 2025; all-stock deal valued at ~$125M.
Combined TTM revenue $235M (+25% QoQ); expected annual cost savings ~$1.7M.
Better Choice Q2 2024 adjusted EBITDA near break-even (-$0.03M); SRx Health had CAD$180M revenue in 2023.
Pro forma fully diluted shares 22.9M; insiders own ~75%; net tangible book value $4.07/share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.